Stockscreener 앱 받기
2.15
47.26%
0.69
시간 외 거래:
2.15
전일 마감가:
$1.46
열려 있는:
$1.63
하루 거래량:
8.82M
Relative Volume:
10.36
시가총액:
$214.98M
수익:
$100.56M
순이익/손실:
$-119.05M
주가수익비율:
-1.748
EPS:
-1.23
순현금흐름:
$-231.16M
1주 성능:
+48.28%
1개월 성능:
+41.45%
6개월 성능:
+22.86%
1년 성능:
-57.84%
1일 변동 폭
$1.54
$2.22
1주일 범위
$1.42
$2.22
52주 변동 폭
$0.87
$6.37
알렉터 Stock (ALEC) Company Profile
명칭
Alector Inc
전화
415-231-5660
주소
131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO
ALEC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALEC
Alector Inc
|
2.15 | 142.99M | 100.56M | -119.05M | -231.16M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
알렉터 Stock (ALEC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-28 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-12-17 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-12-16 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-04 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-11-29 | 재확인 | H.C. Wainwright | Buy |
| 2024-11-26 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-14 | 업그레이드 | Stifel | Hold → Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-09-25 | 개시 | Goldman | Sell |
| 2023-09-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-09-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-04-13 | 개시 | Goldman | Sell |
| 2022-03-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-27 | 개시 | William Blair | Outperform |
| 2021-01-15 | 재개 | BofA Securities | Buy |
| 2020-06-24 | 개시 | H.C. Wainwright | Buy |
| 2020-04-28 | 개시 | Goldman | Buy |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-02-19 | 개시 | Stifel | Buy |
| 2019-11-21 | 개시 | BTIG Research | Buy |
| 2019-03-04 | 개시 | Barclays | Overweight |
| 2019-03-04 | 개시 | BofA/Merrill | Buy |
| 2019-03-04 | 개시 | Morgan Stanley | Overweight |
| 2019-03-04 | 개시 | SVB Leerink | Outperform |
모두보기
알렉터 주식(ALEC)의 최신 뉴스
Earnings Update: Alector, Inc. (NASDAQ:ALEC) Just Reported And Analysts Are Boosting Their Estimates - Yahoo Finance
Alector (ALEC): A High-Conviction Biotech Play with Near-Term Catalysts and a Clear Path to Value Creation - AInvest
Alector 2025 Q2 Earnings Continued Losses Despite Narrowing Net Income - AInvest
Transcript : Alector, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Alector's 30% Surge: A Biotech Breakout or a Volatility Trap? - AInvest
Promising Advancements in Alector’s Clinical Trials Highlighted by Positive Biomarker Data and Therapeutic Potential - TipRanks
H.C. Wainwright Maintains Alector(ALEC.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛
BofA Securities Maintains Alector(ALEC.US) With Sell Rating, Maintains Target Price $1 - 富途牛牛
Alector Tightens Losses As Analysts Set Sights Higher - Finimize
Earnings call transcript: Alector beats Q2 2025 EPS and revenue forecasts - Investing.com
Alector's Q2 Earnings Call: Promising Progress in Dementia Trials Amidst Strategic Challenges - AInvest
Alector's Promising Future: Buy Rating Backed by FDA-Endorsed Trials and Amendments - AInvest
Alector Inc (ALEC) Q2 2025 Earnings Call Highlights: Promising Advances in Dementia Trials Amidst Strategic Challenges - GuruFocus
Alector Inc (ALEC) Q2 2025 Earnings Call Highlights: Promising A - GuruFocus
Alector Advances Neurodegenerative Therapies Amid Financial Updates - TipRanks
Promising Developments and Strong Financials Make Alector a Compelling Buy - TipRanks
Alector’s Promising Future: Buy Rating Backed by Strategic Trials and FDA-Endorsed Amendments - TipRanks
Alector (ALEC) Q2 Revenue Falls 48% - The Globe and Mail
Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates - ca.finance.yahoo.com
Alector: Q2 Earnings Snapshot - San Antonio Express-News
Alector earnings beat by $0.17, revenue topped estimates By Investing.com - Investing.com South Africa
Alector sees FY25 revenue view $13M-$18M, consensus $12.56M - TipRanks
Alector earnings beat by $0.17, revenue topped estimates - Investing.com Canada
Alector: A Biotech Gem Navigating the Post-IRA Landscape with Robust Financials and Promising Pipeline - AInvest
Alector Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Alector Nears Crucial Phase 3 Results for First-Ever FTD Treatment as Cash Hits $307M - Stock Titan
Should I hold or sell Alector Inc. stock in 2025Invest smarter with daily stock recommendations - Jammu Links News
What makes Alector Inc. stock price move sharplyBoost your wealth with consistent growth stocks - Jammu Links News
How strong is Alector Inc. company’s balance sheetTremendous wealth creation - Jammu Links News
What institutional investors are buying Alector Inc. stockPowerful profit generation - Jammu Links News
Is Alector Inc. a good long term investmentInvest smarter with actionable market insights - Jammu Links News
How does Alector Inc. generate profit in a changing economyAchieve breakthrough financial results today - Jammu Links News
What is the dividend policy of Alector Inc. stockIdentify undervalued stocks ready to soar - Jammu Links News
What is Alector Inc. company’s growth strategyBuild a diversified portfolio for stability - Jammu Links News
Alector Inc. Stock Analysis and ForecastGet exclusive access to professional stock picks - Jammu Links News
How does Alector Inc. compare to its industry peersDiscover high-impact stocks for growth - Jammu Links News
Is it the right time to buy Alector Inc. stockHigh-yield investments - Jammu Links News
Why is Alector Inc. stock attracting strong analyst attentionAchieve rapid financial growth with smart picks - Jammu Links News
What are analysts’ price targets for Alector Inc. in the next 12 monthsBuild a diversified portfolio for steady profits - Jammu Links News
Alector’s Latozinemab Study: A Promising Step in Neurodegenerative Disease Treatment - The Globe and Mail
How to build a custom watchlist for Alector Inc.Sector Rotation Strategy for Smart Traders - Newser
Market reaction to Alector Inc.’s recent newsRSI and MACD Signal Summary with Trends - Newser
Identifying reversal signals in Alector Inc.Free AI Powered High Return Stock Calls - Newser
Why Alector Inc. stock attracts strong analyst attentionPortfolio Risk Distribution Analysis Tool - Newser
Alector Inc expected to post a loss of 46 cents a shareEarnings Preview - TradingView
Alector's Latozinemab Study Advances Neurodegenerative Disease Treatment - AInvest
When is Alector Inc. stock expected to show significant growthExpert Picks Watchlist For Every Investor - Jammu Links News
What is the risk reward ratio of investing in Alector Inc. stockFinancial News Review For Consistent Profits - Jammu Links News
Risk adjusted return profile for Alector Inc. analyzedReal Chart Based Opportunity Identification - Newser
How to recover losses in Alector Inc. stockShort-Term Stock Trend Forecast Guide - Newser
Is Alector Inc. stock entering bullish territoryRSI and MACD Signal Summary with Trends - Newser
알렉터 (ALEC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):